(Q40241848)

PubMed publication ID

23836412

18 September 2017

title

Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6351424&resulttype=core&format=json

13 May 2020

8

Jeffrey Schlom

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6351424&resulttype=core&format=json

13 May 2020

1

James L Gulley

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6351424&resulttype=core&format=json

13 May 2020

9

Peter A Pinto

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6351424&resulttype=core&format=json

13 May 2020

author name string

Christopher R Heery

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6351424&resulttype=core&format=json

13 May 2020

Ravi A Madan

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6351424&resulttype=core&format=json

13 May 2020

Beatriz A Walter

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6351424&resulttype=core&format=json

13 May 2020

Maria J Merino

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6351424&resulttype=core&format=json

13 May 2020

William L Dahut

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6351424&resulttype=core&format=json

13 May 2020

Kwong-Yok Tsang

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6351424&resulttype=core&format=json

13 May 2020

publication date

9 July 2013

1 reference

PubMed publication ID

23836412

Cancer Immunology, Immunotherapy

18 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6351424&resulttype=core&format=json

13 May 2020

volume

62

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6351424&resulttype=core&format=json

13 May 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6351424&resulttype=core&format=json

13 May 2020

page(s)

1521-1531

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6351424&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00262-013-1448-0

13 May 2020

exact match

0 references

cites work

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1448-0

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1448-0

Therapeutic Cancer Vaccines in Prostate Cancer: The Paradox of Improved Survival Without Changes in Time to Progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1448-0

Therapeutic vaccines in metastatic castration-resistant prostate cancer: principles in clinical trial design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1448-0

Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1448-0

Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1448-0

Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1448-0

The danger model: a renewed sense of self

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1448-0

Local delivery of vaccinia virus expressing multiple costimulatory molecules for the treatment of established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1448-0

Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1448-0

Intratumoral vaccination and diversified subcutaneous/ intratumoral vaccination with recombinant poxviruses encoding a tumor antigen and multiple costimulatory molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1448-0

Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcino

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1448-0

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1448-0

Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1448-0

Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1448-0

Successful granulocyte-colony stimulating factor treatment of Crohn's disease is associated with the appearance of circulating interleukin-10-producing T cells and increased lamina propria plasmacytoid dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1448-0

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1448-0

Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1448-0

Clinical safety of a viral vector based prostate cancer vaccine strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1448-0

A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1448-0

Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1448-0

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1448-0

Chronic lymphocytic leukemia (CLL) cells genetically modified to express B7-1, ICAM-1, and LFA-3 confer APC capacity to T cells from CLL patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1448-0

Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1448-0

Impact of tumour volume on the potential efficacy of therapeutic vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1448-0

Therapeutic vaccines: the ultimate personalized therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1448-0

Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1448-0

Epitope spreading contributes to effective immunotherapy in metastatic melanoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1448-0

Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1448-0

Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1448-0

Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1448-0

CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1448-0

Immunity to murine prostatic tumors: continuous provision of T-cell help prevents CD8 T-cell tolerance and activates tumor-infiltrating dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1448-0

Combination therapy of an orthotopic renal cell carcinoma model using intratumoral vector-mediated costimulation and systemic interleukin-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1448-0

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1448-0

Long-Term Survival for Patients With Non–Small-Cell Lung Cancer With Intratumoral Lymphoid Structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-013-1448-0

A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer.

21 January 2018

1 reference

12 December 2020

Phase i study of intravesical vaccinia virus as a vector for gene therapy of bladder cancer

1 reference

12 December 2020

Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.

1 reference

12 December 2020

Intratumoral delivery of vector mediated IL-2 in combination with vaccine results in enhanced T cell avidity and anti-tumor activity

1 reference

12 December 2020

Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

1 reference

12 December 2020

Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules

1 reference

12 December 2020

Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma

1 reference

12 December 2020

CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer

1 reference

12 December 2020

10.1007/S00262-013-1448-0

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6351424&resulttype=core&format=json

Dimensions Publication ID

13 May 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6351424&resulttype=core&format=json

13 May 2020

PubMed publication ID

23836412

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6351424&resulttype=core&format=json